U.S. Markets closed

Curis, Inc. (CRIS)

NASDAQ Global Market - NASDAQ Global Market Delayed Price. Currency in USD
Add to watchlist
1.63-0.02 (-1.21%)
At close: 4:00PM EDT

1.63 0.00 (0.00%)
After hours: 4:43PM EDT

People also watch
ARQLCERSAGENARRYCYTR
  • P
    Pharmaherooooooo
    Pharmaherooooooo

    SLNO (MC $16 M) BLOCKBUSTER in Phase 3 /Rare Disease & Orphan Status + 3 Approved Products = REAL Unknown low float stock with 1000% upside Potential and more .Next billion dollar rare disease company like SRPT here .GLTA

    Soleno therapeutics (SLNO)

    Market Cap $16 Million
    Cash: $8 Million
    Price $0.35

    Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)

    Initiating Coverage June 26, 2017
    http://www.lifescicapital.com/wp-content/uploads/Soleno.pdf

    •Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete

    Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.

    Market Opportunity for PWS is Substantial.

    While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE)
    Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.

  • P
    Peter
    Peter
    ESMO 2017 Congress, 11.09.2017, 09:15 - 10:45, Bilbao Auditorium
    Download Pdf Calendar Export Share
    1141PD - CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study
    J. Powderly (Huntersville, United States of America) M. R. Patel (Sarasota, United States of America) J. J. Lee (Pitsburgh, United States of America) J. Brody (New York, United States of America) F. Meric-Bernstam (Houston, United States of America) E. Hamilton (Nashville, United States of America) S. Ponce Aix (Madrid, Spain) J. Garcia-Corbacho (Barcelona, Spain) Y. Bang (Seoul, Korea, Republic of) M. Ahn (Seoul, Korea, Republic of) S. Rha (Seoul, Korea, Republic of) K. Kim (Seoul, Korea, Republic of) M. Gil Martin (Barcelona, Spain) H. Wang (Lexington, United States of America) A. Lazorchak (Lexington, United States of America) T. Wyant (Lexington, United States of America) A. Ma (Lexington, United States of America) S. Agarwal (Lexington, United States of America) D. Tuck (Lexington, United States of America) A. Daud (San Francisco, United States of America)
  • M
    Maira
    Maira
    Wrong board.
  • K
    Ken
    Ken
    Thanks for the data. Hope Cris treatment works to treat many. Also hope stock price rise is large.
  • P
    Peter
    Peter
    With 907 being close to "mothballed," i.e, prospect of generating revenue next to nil for another three years if ever, what is propping up the price of this stock? I assume it must be the possibility that CA-170 will be potent enough to generate anti-tumor actitvity. Last November as a result of news at SITC stock price popped from $2.40 to $3.40 because the small molecule produced a seven fold increase in percentage of circulating CD8 + T cells with 24 hours of dosing. What could Curis disclose at ESMO in early September regarding clinical profile of CA-170 that might cause the street to take notice that the small molecule approach to disrupting immune checkpoints could disrupt the currently more favored approach of antibody immune checkpoint inhibitors? I presume it would have to be data showing an appreciable clinical benefit in some of the 30 patients that have been dosed with CA-170.
  • J
    JD
    JD
    Ah memories.... 1/21/15
    New pipeline of Immuno-oncology drug candidates: exclusive, multi-year partnership with Aurigene

    PD-L1, orally available small molecule antagonist: IND filing expected in 2015

    Multiple other immune checkpoint pathways: candidate antagonists under optimization

    Precision drug candidates to address hematologic cancers

    CUDC-907: Phase 1, active in diffuse large B cell lymphoma. Phase 2 expected in 2015

    IRAK4, orally available small molecule antagonist : IND filing expected in 2015

    CUDC-427: Phase 1, focusing clinical studies in lymphoma (DLBCL, MALT)

    CUDC-305 (Debio 0932): expect Phase 2 trial in systemic mastocytosis in 2015

    Erivedge® for basal cell carcinoma – Roche/Genentech

    Approved in over 50 countries, royalty revenues to Curis
  • P
    Peter
    Peter
    conference call over: 907 stalled out, it is on to ESMO Sept 8-12 conference where Curis will present clinical profile data of CA-170 to include clinical benefit. Data showing tumor shrinkage would be helpful.
  • M
    Mario
    Mario
    LOOKING FORWARD
    June 30, 2017: cash $ 51M. December 31, 2017: $ 25M. And the company will run out of cash on 2Q, 2018.
    That’s mean CRIS will have to obtain money in December, 2017 or January, 2018 (nobody wait to the last minute).
    How much money? CRIS needs $ 60M to finance all the 2018 business. With a market cap near to $ 200M (pps 1.30-1-50 range) is not acceptable to issue 40M of shares. That would represent a dilution of 30%. I think the pps should be in a 2.00-3.00 range for a comfortable public offering.
    Could raise the pps to a range of 2-3 per December? Yes. The key –today- would seem to be in September presentation of CA-170 at the ESMO conference (Ali, conference call). I think the CRIS submission anticipates that the result is positive. No one would make a presentation to say that CA-170 does not work. Other news will be the IND filing for CA-4948. Other news? (low probability): Roche and vismodegib-myelofibrosis program (vismodegib IPF study was withdrawn). Two additional points are: 1) We have to finish understanding the results published yesterday on CUDC-407. They are bad for the short term, but they can be robust from a long term perspective; 2) Sad but true, when there is an opportunity of a public offering of common stock, Cowen, RBC, Roth Capital and other banks do their work (it is understood?).
    Alternatives to the public offering: 1) buyout (I don’t believe); partnering CUDC-407 (low probability); other things I don’t see (moderate probability).
    Comments?
  • p
    playsmart
    playsmart
    Set to fly high tomorrow.
  • F
    Fuji
    Fuji
    Many small biotechs like curis fail not because they dont poses drug candidates but MAINLY BECAUSE OF LAX LEADERSHIP AT THE TOP. You can clearly see in this case that Ali is now trying to blame "multi-site" testing to the lower ORR compared to Ph1. Clinical trial successes depend a lot on conducting a very very very carefully planned trial. And for planning you dont need a decade. These guys are sitting on a decent drug candidate which could atleast be used on a small population of DLBCL patients but due to GROSS NEGLIGIENCE AND INEPT business as and scientific leadership CRIS is almost setup for a failure. ALI IS NOW FOCUSED ON POSTERS/PRESENTATIONS......#$%$???? who cares. All investors are interested in is FAST, WELL PLANNED CLINICAL TRIALS. WITH THOSE....IF THE DRUG FAILS THEN IT FAILS. WHY DRAG THIS ALONG.NOW THEY ARE PROJECTING A SMALL MOLECULE PD1/PDL-1 MODULATOR...........REALLY?????????? I think this is purely to make sure their salaries continue. BOTTOM LINE= MAJOR INVESTORS ARE TO BE BLAMED. THEY NEED TO SPEAK UP AND RAISE ISSUE WITH THE MANAGEMENT STYLE. There was only one analyst (the one who spoke towards the end) that probed this idiot a bit seriously. Others WERE SATISFIED WITH HIS EXPLANATIONS!!!!!!!LOL
  • F
    Fuji
    Fuji
    The results are obviously not Ali's fault but they certainly need to speed up the programs. sitting around and pushing trials slowly is killing the investor. Either make it work or lets shut the shop.
  • F
    Fuji
    Fuji
    whats going on????
  • D
    David
    David
    Looks like Ali #$%$ up another trial and investor$1.00 by weeks end
  • M
    Mario
    Mario
    Today the pps recovered everything lost yesterday.
    Was the conference call bad, good or neutral? What will say today those who insulted yesterday?
  • F
    Fuji
    Fuji
    Old timers here.. any thoughts on why Mani Mohindru left at this stage? Saw a news item that she joined clara pharma as CFO/CSO. Why leave at this stage of development? thoughts?
  • F
    Fuji
    Fuji
    I listened to the recorded call. Here is what I think. Curis has a molecule 907 with significant potential. Remember there were no significant adverse events, the ORR is reasonable for a monotherapy with CR.
    THE ISSUE I SEE IS.........................PASSIVE MANAGEMENT STYLE. They are taking this along as if it was some research project. We could hear Ali saying, we have to study the patient profile and myc status. This is unfortunately not how an accountable management should behave. He has no idea on the next phase. WHY NOT OUTSOURCE 907??????
    FIRE ALI AND GET SOME AGGRESSIVE CSO/CEO TO TAKE OVER.. WONDER WHAT AURIGENE IS THINKING NOW.
    YOUR PASSIVENESS IS CRIMINAL MR ALI
  • D
    David
    David
    Big dump coming up tomorrow
    Someone was tipped off today that badness is on the horizon

    Arigene may have pulled out on less than expected efficacy
  • S
    Scott
    Scott
    Up 17 cents today, is this just a dead-cat bounce or what?
  • D
    David
    David
    Told you.......... Ali f'd up another trial and continues to reward himself and management for failures..........This management is worthless and us shareholders are paying the price............... Ali has got to go!
  • T
    T
    T
    First Eagle unchanged ownership in Q2.